Malignant tumours

Advanced search

Adjuvant and neoadjuvant therapy of tumors of the gastrointestinal tract.

Full Text:


Tumors of the gastrointestinal tract (GIT) - is an extremely heterogeneous group of tumors and characterized by a variety of morphological, genetic characteristics and different approaches to treatment. Most of the tumors can be removed surgically, but as the results of follow-up show, even in case of radical surgical treatment at least half of patients die because of distant metastases. It means that at the time of radical surgery a large number of patients have undetectable micrometastases and therefore the disease is systemic. Adjuvant therapy is a drug therapy after radical surgery, aimed to eradicate distant micrometastases in order to increase overall and disease-free survival. There is no doubt that strong attention of oncologists to the adjuvant treatment of gastrointestinal tumors is dictated by a will to achieve increase in progression-free survival after radical surgery. This period of life of a cancer patient can be equated to a period of temporary "recovery" when the patient for a considerable length of time does not need any special treatment, leads an active lifestyle and may even go back to work. From the point of view of the public healthcare adjuvant chemotherapy (CT) is the most important. For today research and the searching of optimal regimes of adjuvant chemotherapy of gastrointestinal tumors continue. The basic principle of adjuvant therapy regimen selection - is proved high efficiency in the treatment of metastatic disease. At the same time neoadjuvant regimens are studied. The aim of neoadjuvant chemotherapy is to reduce tumor size, to provide partial destruction of tumor cells (ideally - to achieve complete morphological regression), that allows to performs the operation of smaller volume than the operation that would be performed without neoadjuvant chemotherapy. Currently, principles based on randomized clinical trials with a high level of evidence are established for the selection a regimen of adjuvant and neoadjuvant chemotherapy of gastrointestinal tumors.

About the Authors

M. V. Kopp
ГБУЗ «Самарский областной клинический онкологический диспансер», г. Самара.
Russian Federation

I. A. Koroleva
ГБУЗ «Самарский областной клинический онкологический диспансер», г. Самара.
Russian Federation


1. GASTRIC «Global Advanced / Adjuvant stomach Tumor Research through International Collaboration» Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010 May 5;303 (17):1729-1737.

2. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine. N Engl J Med 2007; 357:1810-1820.

3. Bang Y. J., Kim Y. W., Yang H. K., et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet 2012; 379: 315-321.

4. Bajetta E., Floriani I., Bartolomeo M. D., et al. Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) / folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU / LV regimen as postoperative treatment for radically resected gastric cancer. J Clin Oncol 30, 2012 (suppl; abstr LBA4001).

5. Cunningham D., Allum W. H., Stenning S. P.,Thompson J. N., Van de Velde C. J., Nicolson M. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.

6. Boige, V. and Pignon, J. P. Final results of a randomized trial comparing preoperative 5-fluorouracil (F) / cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Proceedings of the ASCO 2007 Annual Meeting.

7. Schuhmacher, C., Schlag, P., Lordick, F., Hohenberger, W., Heise, J. and Haag, C. Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. In: Proceedings of the ASCO 2009 Annual Meeting.

8. Moertel C. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon cancer. New Engl J Medicine, 1990, 322:352-358

9. O’Connell M. J. et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246.

10. Andre T., Colin P., Louvet C., et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21 (15): 2896-903.

11. Andre T., Boni C., Mounedji-Boudiaf L. et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer N Engl J Med 2004; 350:2343-2351.

12. Haller D. G., Tabernero J., Maroun J., de Braud J., Price T., Van Cutsem E., et al. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU / LV for stage III colon cancer (NO16968 / XELOXA study). Eur J Cancer Supplements 2009; 7:4.

13. Schmoll al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25:102

14. Haller D. G., Tabernero J., Maroun J., de Braud F., Price T., Van Cutsem E., Hill M., Gilberg F., Rittweger K., Schmoll H. J. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011, 29:1465-1471.

15. Saltz L. B., Niedzwiecki D., Hollis D., Goldberg R. M., Hantel A., Thomas J. P., Fields A. L., et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25 (23):3456-3461.

16. Ychou M., Hohenberger W., Thezenas S., Navarro M., Maurel J., et al. A randomized phase III study comparing adjuvant 5-fluorouracil / folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20 (12):1964-1970.

17. Van Cutsem E., Labianca R., Bodoky G., Barone C., Aranda E., Nordlinger B., Topham C., et al. Randomized phase III trial comparing biweekly infusional fluorouracil / leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27 (19):3117-3125.

18. de Gramont А. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. The Lancet Oncology, 2012, Volume 13, Issue 12, Pages 1225-1233.

19. Alberts S. R., Sargent D. J., Smyrrk T. C, et al. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage

20. III colon cancer: results from NCCTG intergroup phase III trial NO147, Journal of Clinical Oncology, vol. 28, no. 18, supplement, article 959s, 2010, supplement; abstract CRA3507.

21. Goldberg R. M., Sargent D. J., Thibodeau N., et al., Adjuvant mFOLFOX6 plus or minus cetuximab in patients with KRAS mutant resected stage III colon cancer: NCCTG intergroup phase III trial NO147. Journal of Clinical Oncology, vol. 28, no. 15, supplement, article 262s, 2010.

22. Schmoll H. J., Van Cutsem E., Stein A., et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer.

23. А personalized approach to clinical decision making. Ann Oncol. 2012 Oct; 23 (10):2479-516.

24. Simon I., Roepman P., Schlicker A., et al. Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT). J Clin Oncol 30: 2012 (suppl 34; abstr 333).

25. Roh M. S., Yothers G. A., O’Connell M. J., et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol. 2011;29 (suppl 15). Abstract 3503 and oral presentation at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2011; Chicago, IL.

26. R del C., Liersch T., Becker H., et al.: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German

27. CAO / ARO / AIO-04 randomised phase 3 trial. Lancet Oncol 13 (7): 679-87, 2012.

28. Schrag D., Weiser M. R., Goodman K. A.,

29. Reidy D. L., Cercek A., Gonen M., et al. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. J Clin Oncol (Meeting Abstracts) 2010;28:3511.

30. Valentini V., van Stiphout R. G., Lammering G., Gambacorta M. A., Barba M. C., et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011; 29: 3163-3172.

For citation:

Kopp M.V., Koroleva I.A. Adjuvant and neoadjuvant therapy of tumors of the gastrointestinal tract. Malignant tumours. 2013;(2):33-42. (In Russ.)

Views: 11535

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)